EGFR and non-small cell lung carcinoma: Questions about the ability of the UK National Health Service (NHS) to implement one of the case study examples of precision medicine, EGFR mutation testing and gefitinib, a specific epidermal growth factor receptor (EGFR) inhibitor licenced for patients with EGFR mutation-positive non-small cell lung cancer, without “substantial investment in time and resources” have been raised.